COMPARATIVE ANALYSIS OF THE UKRAINIAN AND POLISH PHARMACEUTICAL MARKETS OF ANTIFUNGAL DRUGS FOR SYSTEMIC APPLICATION
DOI:
https://doi.org/10.11603/2312-0967.2024.2.14745Abstract
The aim of the work. To conduct a study of the range of antifungal drugs for systemic use (ATX Code J02А) in Ukraine and to analyze the conformity of the Ukrainian pharmaceutical market to European markets using the example of Poland.
Materials and Methods. Official sources of information were used in this work, data were processed and systematized using statistical, logical, and graphic methods.
Results and Discussion. As a result of the comparative analysis of the Ukrainian and Polish pharmaceutical markets, it was established that the most numerous in the J02A group "Systemic antifungal drugs" is the J02АС01 subgroup, 50.85%, and 33.33%, respectively, in which the active pharmaceutical ingredient is fluconazole. The most common medicinal form in Ukraine is capsules (43.22%), and in Poland - powders for infusions (36.88%). It has been investigated that medicinal products of the J02A group are monopreparations. The pharmaceutical market of systemic antifungal drugs in Poland has an almost equal number of Polish and imported drugs, while the Ukrainian market is more import-dependent. India is the leader in the import of systemic anti-fungal drugs to Ukraine, while the share of drugs from importing countries in Poland is more balanced. Despite the small number of domestic drugs in the J02A group (24.58%), they are manufactured at 13 Ukrainian pharmaceutical enterprises.
Conclusions. The analysis of the Ukrainian and Polish pharmaceutical markets of systemic anti-fungal drugs showed a sufficient supply of medicines of the J02A group for rational pharmacotherapy of fungal diseases. Ukrainian pharmaceutical companies produce only certain subgroups of drugs of the J02A group (J02AC01, J02AC02, J02AC03, J02AC04). Despite a certain import dependence and a slight difference in the assortment, the Ukrainian pharmaceutical market is filled with antifungal drugs of systemic action similar to the Polish one, indicating compliance with the European pharmaceutical markets. An important aspect is the further development of domestic production and the strategy of stimulating domestic pharmaceutical companies to reduce import dependence.
References
Country burden of fungal disease publications and abstracts [Internet]. Global Action Fund for Fungal Infections. Available from: https://gaffi.org/media/countryfungal-disease-burdens/ [Accessed 20th July 2023].
Denning D. Global burden and mortality of severe fungal diseases. SSRN. Available from: https://ssrn.com/abstract=4560971. DOI: 10.2139/ssrn.4560971.
Biletska VL, Kysel AA, Kachan RV. Stvorennia novykh zasobiv dlia profilaktyky ta likuvannia zakhvoriuvan, vyklykanykh dermatofitamy i drizhdzhepodibnymy hrybamy. Tekhnolohii ta dyzain. 2019; 4 (33):1-12. Ukrainian
Mazur IP. Hrybkovi urazhennia slyzovoi obolonky rota. Suchasna stomatolohiia. 2020; 3:72-77. DOI: 10.33295/1992-576X-2020-3-72. Ukrainian
Kovalevskyy NI, Zamaziy TM, Novikova IV. Study of prevalence and antifungal resistance of Candida species in upper and lower respiratory tract infections. Aktualʹnaâ infektologiâ. 2020;8(5-6):25-28. URL: http://www.mif-ua.com/archive/article/49907.
Brown GD, Denning DW, Gow NAR, Levitz S, Netea M, White T. Human fungal infections: the hidden killers. Sci Transl Med. 2012;4(165rv13). DOI: 10.1126/scitranslmed.3004404.
Boychuk TS, Zavystivska TO, Stepanova VO, Kachan RV. Antimicrobial agents for treatment and prevention of infections. Technologies and Design. 2020;4(37):1-12.
Oksenyuk OY, Hudzenko OP, Shpychak OS. Analysis of the pharmaceutical market of Ukraine of antifungal drugs. Social pharmacy in health care. 2020;6(1):69-80.
Healthcare Development Strategy until 2030: expectations and priorities. [Internet]. Available from: https://moz.gov.ua/uploads/ckeditor/%D0%A1%D1%82%D1%80%D0%B0%D1%82%D0%B5%D0%B3%D1%96%D1%8F/UKR%20Health%20Strategy%20Feb%2024.2022.pdf.
Derzhavnyy reyestr likarsʹkykh zasobiv Ukrayiny [State Register of Medicines of Ukraine]. Available from: http://www.drlz.kiev.ua/ Ukrainian.
State Register of Medicines of Poland. [Internet]. Available from: https://rejestrymedyczne.ezdrowie.gov.pl/rpl/search/public.
Compendium Directory [Internet]. Available from: http://preparaty.org/atc/J02A.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pharmaceutical Review / Farmacevtičnij časopis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
